Koenig, Wolfgang http://orcid.org/0000-0002-2064-9603
Conde, Lorena Garcia
Landmesser, Ulf
Leiter, Lawrence A.
Ray, Kausik K.
Schwartz, Gregory G.
Wright, R Scott
Han, Jackie
Raal, Frederick J.
Funding for this research was provided by:
Novartis Pharma AG, Basel, Switzerland
Article History
Accepted: 1 December 2022
First Online: 23 December 2022
Declarations
:
: The study protocols of the ORION-9, ORION-10, and ORION-11 trials were identical and approved by the institutional review board or independent ethics committee of each participating institution.
: Informed consent was obtained from all individual participants included in the trials.
: Not applicable.
: WK reports receiving consulting fees and lecture fees from AstraZeneca, Novartis, and Amgen; consulting fees from Pfizer, The Medicines Company, DalCor Pharmaceuticals, Kowa, Corvidia Therapeutics, Esperion, Genentech, OMEICOS, Novo Nordisk, LIB Therapeutics, and Daiichi Sankyo; lecture fees from Berlin-Chemie, Bristol-Myers Squibb, and Sanofi; and grant support and provision of reagents from Singulex, Abbott, Roche Diagnostics, and Dr Beckmann Pharma.LGC reports being employed by Novartis at the time of study and publication.LL reports receiving lecture fees and advisory fees from AstraZeneca, Amgen, Sanofi, Berlin-Chemie, and Abbott; advisory fees from The Medicines Company; and grant support, lecture fees, and advisory fees from Bayer and Novartis.LAL reports grant support paid to his institution and advisory board fees and fees for CME from Amgen and Novartis; fees for serving on a steering committee and advisory board fees from Esperion; grant support paid to his institution and fees for serving on a steering committee from Kowa and The Medicines Company; and advisory board fees and fees for CME from Amarin, HLS, Merck, and Sanofi.KKR reports receiving support from the National Institute for Health Research (NIHR) Imperial Biomedical Research Centre and support for his institution (Imperial College London) from the NIHR Applied Research Collaboration Northwest London. Prof. Ray also reports receiving lecture fees from Aegerion Pharmaceuticals, Kowa, Cipla, Algorithm, and Zuelling Pharma; grant support paid to his institution, lecture fees, and advisory board fees from Amgen, Regeneron Pharmaceuticals/Sanofi, and Pfizer; lecture fees and fees for serving on steering committees for trials from AstraZeneca and Eli Lilly; fees for serving on steering committees for trials from Cerenis Therapeutics, The Medicines Company, and Esperion; advisory board fees from Akcea Therapeutics, Novartis, Silence Therapeutics, Bayer, and Daiichi Sankyo; lecture fees and advisory board fees from Takeda, Boehringer Ingelheim, and Dr Reddy’s Laboratories; grant support and advisory board fees from Merck Sharp & Dohme; fees for serving on a clinical events adjudication committee from AbbVie; and fees for serving as principal investigator for a trial from Resverlogix.GGS reports receiving research support paid to his institution from AstraZeneca, Resverlogix, Sanofi, Silence Therapeutics, and The Medicines Company and a patent (62/806313) on a method for reducing cardiovascular risk assigned in full to the University of Colorado.RSW reports receiving advisory board fees from Boehringer Ingelheim and past fees for consulting on lipid issues with The Medicines Company.JH reports being employed by Novartis at the time of study and publication.FJR reports receiving advisory board fees and lecture fees from Amgen, Sanofi-Aventis, Regeneron Pharmaceuticals, Novartis, and LIB Therapeutics.